Lipid Metabolic Rewiring in Cancer Drug Resistance: Pathways, Networks, and Therapeutic Strategies
Year: 2026
Type: article
Abstract: Drug resistance limits cancer therapy, and metabolic reprogramming helps tumor cells adapt to therapeutic stress. This review examines how altered lipid uptake, synthesis, storage, and oxidation support survival by changing signaling, membrane composition, energy production, redox balance, and tumor-microenvironment interactions. The SCAP/SREBP axis is a key transcriptional regulator; oncogenic and nutrient signaling (EGFR, PI3K/AKT/mTOR, mutant p53) controls SREBP abundance and activation, and sustained SREBP activity during treatment distinguishes resistant from sensitive cells in several models, including gefitinib-resistant lung cancer and sorafenib/lenvatinib-resistant hepatocellular carcinoma (HCC). MicroRNAs regulate these pathways post-transcriptionally, including ferroptosis-related targets (ACSL4, SLC7A11, GPX4). Inhibitors of lipogenesis, SCAP/SREBP, cholesterol metabolism, fatty-acid oxidation, lipid uptake and storage, phospholipid and sphingolipid signaling, and ferroptosis have improved drug sensitivity in preclinical models. However, many studies show only an association with resistance rather than that modulating a pathway restores sensitivity; findings vary between tumor types; and compensatory rewiring, toxicity, and limited tumor selectivity constrain single-target approaches, while miRNA-based therapeutics remain early-stage. Rational combinations guided by lipidomic and transcriptomic profiling are a priority.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: chemoresistance, lipid metabolism reprogramming, lipogenesis, cholesterol metabolism, fatty acid oxidation, lipid uptake, ferroptosis, microRNA, EGFR signaling, PI3K/AKT/mTOR pathway, mutant p53, gefitinib resistance, sorafenib resistance, lenvatinib resistance, hepatocellular carcinoma, lung cancer, sphingolipid signaling, phospholipid signaling, tumor microenvironment, lipidomics, combination therapy
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7221714555
